Development asset linked to Lei Xiaoming in public FDA and regional records. Mechanism: Sodium channel alpha subunit blocker.
- Mechanism
- Sodium channel alpha subunit blocker
pharma · Cystic Adenomatoid Malformation of Lung, Congenital
Lei Xiaoming
Lei Xiaoming drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Lei Xiaoming pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lei Xiaoming drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.